Though no drugs able to specifically target the SS18-SSX fusion oncoprotein are currently available, compounds able to disrupt its partnering interactions might be expected to reactivate normal gene transcription and elicit anti-tumor effects and clinical response. The gene discussed is SS18; the disease is neoplasm.